Novartis India working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024FY23Mar 2023
——99.03×
41.80×42.28×34.85×
——107.99×
——25.89×
0.59×0.62×0.73×
0.38×0.35×0.39×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

NOVARTIND₹1,812.80

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Inventory Days (DIO)99.03——
Receivable Days (DSO)34.8542.2841.80
Payable Days (DPO)107.99——
Cash Conversion Cycle (days)25.89——
Working Capital Turnover0.730.620.59
Asset Turnover0.390.350.38
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.